Omeros’ (OMER) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Omeros (NASDAQ:OMER) in a report released on Friday morning,Benzinga reports.

A number of other brokerages have also weighed in on OMER. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target for the company. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Thursday. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Omeros currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Up 1.6 %

OMER opened at $9.33 on Friday. The business’s fifty day simple moving average is $9.35 and its 200 day simple moving average is $6.03. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60. The stock has a market cap of $540.67 million, a PE ratio of -4.04 and a beta of 2.01.

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently modified their holdings of OMER. Geode Capital Management LLC raised its position in Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after purchasing an additional 6,839 shares during the last quarter. State Street Corp raised its holdings in shares of Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after acquiring an additional 3,839 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Omeros by 4.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after acquiring an additional 18,454 shares during the period. Bank of New York Mellon Corp boosted its holdings in Omeros by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 31,081 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Omeros by 6.1% during the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after purchasing an additional 6,435 shares during the period. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.